THOUSAND OAKS, Calif., Sept. 8, 2019 /PRNewswire/ — Amgen (AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. The additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities. These data are being presented during an oral presentation at IASLC 2019 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer.

source https://finance.yahoo.com/news/amgen-announces-clinical-data-evaluating-074500708.html?.tsrc=rss